1
|
Bellinato F, Gisondi P, Balato A, Caldarola G, Cammarata E, Campione E, Carugno A, Conti A, Corazza M, Dapavo P, Dattola A, Di Lernia V, Gasperini M, Panduri S, Prignano F, Satolli F, Spisni E, Girolomoni G. Awareness of obesity among patients with psoriasis. J Eur Acad Dermatol Venereol 2024; 38:e391-e393. [PMID: 37909326 DOI: 10.1111/jdv.19617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Accepted: 10/27/2023] [Indexed: 11/03/2023]
Affiliation(s)
- Francesco Bellinato
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - Paolo Gisondi
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - Anna Balato
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy
| | - Giacomo Caldarola
- Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy
- Dermatologia, Dipartimento Universitario Di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Edoardo Cammarata
- Department of Health Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - Elena Campione
- Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Andrea Carugno
- Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
- PhD Program in Molecular and Translational Medicine (DIMET), University of Milan-Bicocca, Milan, Italy
| | - Andrea Conti
- Dermatology Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy
| | - Monica Corazza
- Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
| | - Paolo Dapavo
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Annunziata Dattola
- Unit of Dermatology, Department of Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
| | - Vito Di Lernia
- Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | | | | | - Francesca Prignano
- Dermatology Section, Department of Health Science, University of Florence, Florence, Italy
| | - Francesca Satolli
- Dermatolgy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy
| | - Enzo Spisni
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Giampiero Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| |
Collapse
|
2
|
Michelucci A, Manzo Margiotta F, Granieri G, Salvia G, Fidanzi C, Bevilacqua M, Panduri S, Romanelli M, Dini V. Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum. Adv Skin Wound Care 2024; 37:276-279. [PMID: 38648242 DOI: 10.1097/asw.0000000000000129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
ABSTRACT Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that is challenging to diagnose and treat. Clinicians frequently use fast-acting corticosteroids, which are subsequently combined with slower-acting immunosuppressants to progressively taper the corticosteroid dosage. Current research is focused on the use of monoclonal antibodies (mAbs) directed against target molecules involved in the pathogenesis of PG. However, available data on their efficacy are based on sporadic case reports and clinical experiences, so the authors aimed to evaluate the efficacy of risankizumab, an anti-interleukin-23 mAb, in the management of two complex PG cases. The authors enrolled two patients with PG who were already treated with immunosuppressive therapies. Their management was based on the off-label use of an mAb directed against the p19 subunit of interleukin-23: risankizumab. Patients received subcutaneous injections of 150 mg at the start of treatment, at week 4, and then every 10 weeks thereafter. Systemic therapy was combined with local management of ulcers, based on the principles of TIME (tissue, infection, moisture balance, and epithelialization) applied to the inflammatory and noninflammatory phases of PG. Clinical resolution was obtained at week 24 for patient 1 and week 16 for patient 2 and was maintained until week 40, without adverse effects or disease recurrence. These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management.
Collapse
Affiliation(s)
- Alessandra Michelucci
- In the Department of Dermatology, University of Pisa, Italy, Alessandra Michelucci, MD; Flavia Manzo Margiotta, MD; Giammarco Granieri, MD; Giorgia Salvia, MD; Cristian Fidanzi, MD; and Matteo Bevilacqua, MD, are Dermatology Residents; Salvatore Panduri, MD, is Specialized Physician; Marco Romanelli, MD, PhD, is Full Professor; and Valentina Dini, MD, PhD, is Associate Professor. Acknowledgments: This manuscript describes off-label product use: risankizumab for pyoderma gangrenosum. The authors have disclosed no financial relationships related to this article. Submitted January 13, 2023; accepted in revised form June 23, 2023
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, Prignano F. Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation. Ital J Dermatol Venerol 2024; 159:64-65. [PMID: 37997317 DOI: 10.23736/s2784-8671.23.07648-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2023]
Affiliation(s)
| | | | - Eugenio Capalbo
- Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| | | | - Elia Rosi
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Susanna Rossari
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | - Michela Magnano
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | - Imma Savarese
- Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Nicola Milanesi
- Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Barbara Simoni
- Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy
| | | | - Pietro Rubegni
- Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| | - Antonella DI Cesare
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | | | | | - Emanuele Trovato
- Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy -
| | - Francesca Prignano
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| |
Collapse
|
4
|
Fidanzi C, Mori N, Bevilacqua M, Panduri S, Romanelli M, Janowska A. Trichoepithelioma and tattooing: a causal or casual relationship? Skin Res Technol 2023; 29:e13474. [PMID: 37881056 PMCID: PMC10512203 DOI: 10.1111/srt.13474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 09/12/2023] [Indexed: 10/27/2023]
Affiliation(s)
| | - Nicolò Mori
- Unit of DermatologyUniversity of PisaPisaItaly
| | | | | | | | | |
Collapse
|
5
|
Michelucci A, Dini V, Salvia G, Granieri G, Manzo Margiotta F, Panduri S, Morganti R, Romanelli M. Assessment and Monitoring of Nail Psoriasis with Ultra-High Frequency Ultrasound: Preliminary Results. Diagnostics (Basel) 2023; 13:2716. [PMID: 37627974 PMCID: PMC10453049 DOI: 10.3390/diagnostics13162716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/25/2023] [Accepted: 08/12/2023] [Indexed: 08/27/2023] Open
Abstract
Psoriatic onychopathy is one of the clinical presentations of psoriasis and a well-known risk factor for the development of psoriatic arthritis. High-frequency ultrasounds (HFUS > 20 MHz) have recently been used to evaluate the nail apparatus of healthy and psoriatic subjects. The aim of our study was to detect by means of ultra-high-frequency ultrasound (UHFUS 70-100 MHz) alterations of the nail bed and matrix in patients with psoriatic onychopathy and to monitor these parameters during the treatment with monoclonal antibody (mAb). We enrolled 10 patients with psoriatic onychopathy and naive to previous biologic therapies. Patients were evaluated at baseline, after 1 month and after 3 months from the beginning of mAb therapy by a complete clinical assessment and US evaluation. A UHFUS examination with a 70 MHz probe was performed on the thumbnail (I), the index fingernail (II) and the nail with greater clinical impairment (W). The following measurements were analyzed: nail plate thickness (A), nail bed thickness (B), nail insertion length (C), nail matrix length (D) and nail matrix thickness (E). Among the various parameters analyzed, some measures showed a statistically significant decrease with p-value < 0.05 (t0 WA = 0.52 mm vs. t2 WA = 0.42 mm; t0 WB = 2.8 mm vs. t2 WB = 2.4 mm; t0 WE = 0.76 mm vs. t2 WE = 0.64 mm; t0 IIA = 0.49 mm vs. t2 IIA = 0.39 mm). In conclusion, UHFUS could represent a viable imaging technique for the real-time evaluation and monitoring of psoriatic onychopathy, thus supporting the clinical parameters and revealing any subclinical signs of early drug response.
Collapse
Affiliation(s)
- Alessandra Michelucci
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Valentina Dini
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Giorgia Salvia
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Giammarco Granieri
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Flavia Manzo Margiotta
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Salvatore Panduri
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| | - Riccardo Morganti
- Statistical Support to Clinical Trials Department, University of Pisa, 56126 Pisa, Italy;
| | - Marco Romanelli
- Department of Dermatology, University of Pisa, 56126 Pisa, Italy; (A.M.); (G.S.); (G.G.); (F.M.M.); (S.P.); (M.R.)
| |
Collapse
|
6
|
Dragotto M, Capalbo E, Cartocci A, Manzo Margiotta F, Michelucci A, Rosi E, Ricceri F, Simoni B, Savarese I, Milanesi N, Rossari S, Magnano M, Romanelli M, Rubegni P, Prignano F, Di Cesare A, Panduri S, Pescitelli L, Trovato E. Real-life effectiveness of Risankizumab according to body mass index: results of an Italian multicenter retrospective study. J Eur Acad Dermatol Venereol 2023. [PMID: 37062048 DOI: 10.1111/jdv.19117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 04/07/2023] [Indexed: 04/17/2023]
Affiliation(s)
- Martina Dragotto
- Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| | - Eugenio Capalbo
- Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| | | | | | | | - Elia Rosi
- Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | | | - Barbara Simoni
- Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy
| | - Imma Savarese
- Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Nicola Milanesi
- Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Susanna Rossari
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | - Michela Magnano
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | | | - Pietro Rubegni
- Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| | - Francesca Prignano
- Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - Antonella Di Cesare
- Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | | | | | - Emanuele Trovato
- Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
| |
Collapse
|
7
|
Salvia G, Michelucci A, Granieri G, Manzo Margiotta F, Bevilacqua M, Fidanzi C, Panduri S, Romanelli M, Dini V. An Integrated Systemic and Local Wound Management in Recalcitrant Pyoderma Gangrenosum. INT J LOW EXTR WOUND 2023:15347346221148818. [PMID: 36597572 DOI: 10.1177/15347346221148818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Pyoderma gangrenosum (PG) is a neutrophilic inflammatory dermatosis, whose management still represents a clinical challenge due to frequent unresponsive cases. The aim of our study was to evaluate the efficacy of a novel, combined approach including local wound management, based on the principle of PG-TIME and a systemic therapy with an anti interleukin (IL)-17A monoclonal antibody (mAb). We presented a case of a 37-year-old female patient, affected by multi-refractory PG. The patient was treated with a combined approach of both local and systemic therapy. Wound clinical improvement was assessed by Wound Bed Score (WBS), wound size was evaluated through 3D camera laser scanner, and pain was evaluated with visual analog scale (VAS). After 52 weeks of therapy, the association of local wound management with ixekizumab 80 mg [160 mg at time (T) 0; 80 mg every 2 weeks until week 12; 80 mg every 4 weeks] allowed us to perform skin grafting and obtain complete wound healing. Our clinical case demonstrated the efficacy of a novel combination therapy for the treatment of recalcitrant PG based on IL-17 mAbs and local wound management built on the main features of PG-TIME.
Collapse
Affiliation(s)
- Giorgia Salvia
- Department of Dermatology, 9310University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | - Marco Romanelli
- Department of Dermatology, 9310University of Pisa, Pisa, Italy
| | - Valentina Dini
- Department of Dermatology, 9310University of Pisa, Pisa, Italy
| |
Collapse
|
8
|
Prignano F, Pescitelli L, Trovato E, DI Cesare A, Cuccia A, Mazzatenta C, Pellegrino M, Marsili F, Castelli A, Brandini L, Niccoli MC, Taviti F, Ricceri F, Panduri S, Buggiani G, Ghilardi A, Rubegni P, Romanelli M, Pimpinelli N. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. Ital J Dermatol Venerol 2022; 157:469-479. [PMID: 35785927 DOI: 10.23736/s2784-8671.22.07355-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Psoriasis is a common chronic skin disease characterized by a worldwide distribution and a natural tendency towards progression. According to the many clinical forms, the extension of the disease and the many comorbidities, almost the 20% of the patients require a systemic treatment. Biologics have greatly changed the ongoing of psoriasis and the quality of life of psoriasis patients. After the anti-TNF-alpha, which were the first biologics in use for psoriasis, the improvement in knowledge of the pathogenetic mechanisms underlying the disease has led to the development of a series of more specific therapies for psoriasis. This "second generation" of biologics includes the interleukin (IL)-12/23 inhibitor ustekinumab, IL-17 inhibitors (secukinumab and ixekizumab), the IL-17 receptor A (IL-17RA) antagonist brodalumab, and the IL-23 inhibitors guselkumab, risankizumab and tildrakizumab. This study represents an update of the Tuscany consensus focused on the use of new drugs, such as anti-IL-17 and anti-IL-23 in moderate-to-severe psoriasis and their correct place in therapy according to specific clinical requests and in full respect of the current financial restrictions.
Collapse
Affiliation(s)
- Francesca Prignano
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy -
| | | | - Emanuele Trovato
- Section of Dermatology, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy
| | - Antonella DI Cesare
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| | - Aldo Cuccia
- Unit of Dermatology, San Donato Hospital, Arezzo, Italy
| | | | | | - Franco Marsili
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | | | - Luca Brandini
- Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy
| | | | - Franca Taviti
- Unit of Dermatology, Hospital of Prato, Prato, Italy
| | | | | | - Gionata Buggiani
- Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy
| | | | - Pietro Rubegni
- Section of Dermatology, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy
| | | | - Nicola Pimpinelli
- Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
| |
Collapse
|
9
|
Iannone M, Janowska A, Panduri S, Morganti R, Davini G, Romanelli M, Dini V. Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: the importance of a psychodermatological approach. Exp Dermatol 2022; 31:956-961. [PMID: 35285091 PMCID: PMC9314578 DOI: 10.1111/exd.14563] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 01/18/2022] [Accepted: 03/09/2022] [Indexed: 11/29/2022]
Abstract
Background There is a strong interaction between the immunological and nervous system in the skin. Lesions that are physically disfiguring and chronically relapsing have a high impact on quality of life (QoL) and can result in the emergence of psychiatric disorders. The literature data confirm a higher prevalence of psychiatric disorders in patients with psoriasis, hidradenitis suppurativa (HS) and atopic dermatitis (AD), but such data are compromised by low‐quality evidence due to methodological heterogeneity. Objectives The primary aim was to analyse the prevalence of psychiatric comorbidities in a group of psoriasis, AD and HS patients compared with a control group. The secondary aims were to evaluate the impact of psychiatric comorbidities on the disease development, severity, flare‐ups and QoL. Methods A total of 59 cases and 64 controls were included. Results Generalized anxiety disorder and depressive disorder with anxious distress were found to be risk factors for AD. Age, smoking and substance‐related disorder showed a specific association with HS. Major depressive disorder showed a specific association with dermatology life quality index (DLQI) and all the above disease flare‐ups. Conclusions Atopic dermatitis, psoriasis and HS are associated with psychiatric disorders. A psychodermatological approach improves outcomes in terms of QoL, disease flare‐ups and long‐term management.
Collapse
Affiliation(s)
| | | | | | - Riccardo Morganti
- Department of Clinical and Experimental Medicine Section of Statistics University of Pisa Pisa Italy
| | - Giulia Davini
- Department of Dermatology University of Pisa Pisa Italy
| | | | | |
Collapse
|
10
|
Michelucci A, Margiotta FM, Panduri S, Tonini A, Romanelli M, Morganti R, Janowska A, Dini V. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther 2022; 35:e15339. [PMID: 35088508 DOI: 10.1111/dth.15339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 01/03/2022] [Accepted: 01/23/2022] [Indexed: 11/28/2022]
Abstract
Psoriasis is a skin disorder characterized by chronic inflammation driven by different immunologic pathways, among which the IL-23/Th17 axis plays a pivotal role. For this reason, the use of IL23p19 inhibitors in psoriasis treatment has been evaluated over the years. Guselkumab, a totally human IgG1 lambda monoclonal antibody, that selectively blocks the p 19 subunit of IL- 23 has demonstrated high efficacy and safety throughout several, randomized, double-blind phase III trials (VOYAGE 1 and 2, NAVIGATE and ECLIPSE). We designed a single-center retrospective cohort study in a population consisting of 46 patients followed from December 2018 to April 2021. After a diagnosis of moderate to severe psoriasis, all the patients were considered suitable to receive treatment with Guselkumab. In our population, among those who achieved clinical improvement in terms of Psoriasis Area Severity Index (PASI), PASI 75,90, and 100 were achieved on average on weeks 14,19,21 respectively. We then analyzed a subgroup of our population, consisting of 35 patients, who had an identical follow-up time of 28 weeks, thus observing the trend in mean PASI at subsequent assessments and the number of patients who had reached PASI 75, PASI 90, and PASI 100 at week 4 (10; 3;1), week 12 (12; 13; 11), week 20 (7;6;2) and week 28 (1;4;6), respectively. The results obtained are in line with those obtained from previous studies, thus confirming that Guselkumab is an excellent choice in terms of security, long-term efficacy and overall tolerance.
Collapse
Affiliation(s)
| | - Flavia Manzo Margiotta
- Department of Dermatology, University of Pisa, Pisa, Italy.,Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy
| | | | | | | | - Riccardo Morganti
- Statistical Support to Clinical Trials Department, University of Pisa, Pisa, Italy
| | - Agata Janowska
- Department of Dermatology, University of Pisa, Pisa, Italy
| | - Valentina Dini
- Department of Dermatology, University of Pisa, Pisa, Italy
| |
Collapse
|
11
|
Manzo Margiotta F, Michelucci A, Panduri S, Tonini A, Davini G, Romanelli M, Morganti R, Dini V. Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab. J Eur Acad Dermatol Venereol 2022; 36:e454-e456. [DOI: 10.1111/jdv.17944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 12/04/2021] [Accepted: 01/05/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Flavia Manzo Margiotta
- Department of Dermatology University of Pisa Pisa Italy
- Institute of Life Sciences Scuola Superiore Sant'Anna Pisa Italy
| | | | | | | | - Giulia Davini
- Department of Dermatology University of Pisa Pisa Italy
| | | | - Riccardo Morganti
- Statistical Support to Clinical Trials Department University of Pisa Pisa Italy
| | | |
Collapse
|
12
|
Granieri G, Oranges T, Panduri S, Loggini B, Janowska A, Dini V, Romanelli M. Unusual presentation of angiolymphoid hyperplasia with eosinophilia treated with intralesional and topic corticosteroid combination therapy. Dermatol Reports 2021; 13:9063. [PMID: 34659673 PMCID: PMC8451073 DOI: 10.4081/dr.2021.9063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 03/30/2021] [Indexed: 11/22/2022] Open
Abstract
Angiolymphoid hyperplasia with eosinophilia (ALHE) is an uncommon angioproliferative benign disorder. A 24- year-old Caucasian female patient presented with multiple itchy reddish pearly nodule.
Collapse
|
13
|
Dini V, Janowska A, Faita F, Panduri S, Benincasa BB, Izzetti R, Romanelli M, Oranges T. Ultra-high-frequency ultrasound monitoring of plaque psoriasis during ixekizumab treatment. Skin Res Technol 2021; 27:277-282. [PMID: 33529441 DOI: 10.1111/srt.12942] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 06/04/2020] [Indexed: 02/04/2023]
Abstract
BACKGROUND High-frequency ultrasound (HFUS) is a non-invasive method that detects superficial skin features. Ultra-high frequencies (50-100 MHz) can reveal epidermis and dermis structures. OBJECTIVES In this study, we describe the psoriatic plaque using a new device equipped with a 70 MHz probe (VEVO® MD, Fujifilm, VisualSonics) and we assess the lesion before and after ixekizumab. METHODS We examined the superficial hyperechoic band, the subepidermal hypoechoic band (SLEB), and the vascularization of the plaque in ten patients affected by plaque psoriasis. RESULTS The average superficial hyperechoic band thickness was 0.2157 mm before treatment, 0.1611 mm after 15 days, and 0.1354 mm (P < .05) after 30 days. The SLEB thickness was 0.7535 mm at baseline, 0.3300 mm after 15 days (P < .05), and 0.2007 mm (P < .05) after 30 days. The average percentage vascularization was 50.21% at baseline, 13.15% after 15 days (P < .05), and 5.97% after 30 days. UHFUS assessment highlighted the rapid action of the drug in terms of the decrease in vascularization after 15 days. It revealed a statistically significant reduction in SLEB thickness after 15 days and a significant reduction in the hyperechoic superficial band after 30 days. CONCLUSIONS VEVO® MD provides physicians with high-resolution details of the psoriatic plaque, thus enabling tailored-made treatments.
Collapse
Affiliation(s)
- Valentina Dini
- Department of Dermatology, University of Pisa, Pisa, Italy
| | - Agata Janowska
- Department of Dermatology, University of Pisa, Pisa, Italy
| | - Francesco Faita
- Italian National Research Council Institute of Clinical Physiology, Pisa, Italy
| | | | | | - Rossana Izzetti
- Unit of Dentistry and Oral Surgery, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
| | | | - Teresa Oranges
- Department of Dermatology, University of Pisa, Pisa, Italy
| |
Collapse
|
14
|
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, Gaiani FM, Leite L, Malagoli P, Mendes-Bastos P, Megna M, Messina F, Nidegger A, Odorici G, Panduri S, Piaserico S, Piscitelli L, Prignano F, Ribero S, Valerio J, Torres T. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J DERMATOL TREAT 2019; 31:476-483. [DOI: 10.1080/09546634.2019.1671577] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
| | - Anna Balato
- Department of Advanced Biomedical Sciences, University of Naples Federico II, Napoli, Italy
| | - Curdin Conrad
- Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
| | - Andrea Conti
- Dermatology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - Paolo Dapavo
- Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | | | | | | | | | | | - Matteo Megna
- Department of Dermatology, University of Naples Federico II, Napoli, Italy
| | | | - Alessia Nidegger
- Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
| | - Giulia Odorici
- Dermatology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | | | | | | | | | - Simone Ribero
- Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
| | | | | |
Collapse
|
15
|
Tonini A, Zanframundo S, Panduri S, Marchetti E, Romanelli M, Chiricozzi A. Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis. JAAD Case Rep 2019; 5:484-487. [PMID: 31193589 PMCID: PMC6536743 DOI: 10.1016/j.jdcr.2019.03.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Annalisa Tonini
- Correspondence to: Annalisa Tonini, MD, Via Roma 67, 56126, Pisa, Italy.
| | | | | | | | | | | |
Collapse
|
16
|
Ghilli M, Mariniello MD, Colizzi L, Camilleri V, Janowska A, Dini V, Quattrini Li A, Panduri S, Macchia M, Romanelli M, Roncella M. Breast surgeons dealing with Munchausen syndrome: A self‐induced necrotic phlegmon of the breast treated with surgery, negative pressure and epidermal fractional skin grafting. Breast J 2019; 25:526-527. [DOI: 10.1111/tbj.13261] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2017] [Revised: 01/17/2018] [Accepted: 01/23/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Matteo Ghilli
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | | | - Livio Colizzi
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Valeria Camilleri
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Agata Janowska
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
- Dermatology Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Valentina Dini
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
- Dermatology Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | | | - Salvatore Panduri
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
- Dermatology Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Michela Macchia
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
- Dermatology Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Marco Romanelli
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
- Dermatology Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
| | - Manuela Roncella
- Breast Cancer CenterAzienda Ospedaliero‐Universitaria Pisana Pisa Italy
| |
Collapse
|
17
|
Chiricozzi A, Conti A, Burlando M, Odorici G, Gaiani F, Panduri S, Malagoli P. Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience. Dermatology 2019; 235:213-218. [DOI: 10.1159/000497274] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 01/25/2019] [Indexed: 11/19/2022] Open
Abstract
Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
Collapse
|
18
|
Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opin Biol Ther 2018; 19:1-8. [DOI: 10.1080/14712598.2019.1551354] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Andrea Chiricozzi
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Luca Antonioli
- Pharmacology & Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Salvatore Panduri
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Matteo Fornai
- Pharmacology & Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marco Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Corrado Blandizzi
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| |
Collapse
|
19
|
Russo F, Vispi M, Sirna R, Mancini V, Bagnoni G, Bartoli L, Bellini M, Brandini L, Caproni M, Castelli A, Cecchi R, Cuccia A, Fimiani M, Grazzini M, Marsili F, Mazzatenta C, Niccoli MC, Panduri S, Peccianti C, Pecenco S, Pimpinelli N, Prignano F, Ricceri F, Romanelli M, Rossari S, Taviti F, Volpi W, Pellegrino M. Tuscan consensus on the use of UVBnb phototherapy in the treatment of psoriasis. GIORN ITAL DERMAT V 2018; 154:99-105. [PMID: 30375219 DOI: 10.23736/s0392-0488.18.06223-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Psoriasis (PSO) is traditionally defined as an immune-mediated, inflammatory dermatological disease characterized by a chronic-relapsing course and associated with multifactorial inheritance (genetic predisposition and influence of various environmental factors). Considered until recently a dermatological disease only, today PSO is correctly known as a systemic one because of the involvement of multiple organs with important impact on social life and relationships. PSO is found in the 0.3-4.6% of the world's population, while its prevalence in the Italian population is estimated at 2.8%. Therefore, if we consider that in Tuscany more than 100,000 people out of 3,672,202 suffer of psoriasis, it is of paramount importance to focus on a shared clinical and therapeutic protocol to manage the disease. With the aim of ensuring diagnostic-therapeutic suitability, high levels of care and standardization of treatment, a unique clinical-therapeutic management model has been developed and validated in Tuscany, involving all accredited regional dermatological centers. Among the possible alternatives to be implemented in the treatment of patients with mild, moderate-severe psoriasis, UVBnb phototherapy is widely used alone or in association with other systemic and non-systemic devices. Despite this, there is still no universally shared therapeutic protocol. In this context the CO.FO.TO working group (Consensus Fototerapia Toscana) is born with the aim of defining and validating the main guidelines in the use of phototherapy with UVBnb in psoriasis; the guidelines are based both on the real-life experience of the different centers of reference in the region and on the revision of the recent literature.
Collapse
Affiliation(s)
- Filomena Russo
- Section of Dermatology, Department of Clinical Medicine and Immunological Science, University of Siena, Siena, Italy -
| | - Martina Vispi
- Section of Dermatology, Department of Dermatology, Misericordia Hospital, Grosseto, Italy
| | - Riccardo Sirna
- Section of Dermatology, Department of Dermatology, Misericordia Hospital, Grosseto, Italy
| | - Virginia Mancini
- Section of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy
| | | | - Laura Bartoli
- Unit of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Mauro Bellini
- Unit of Dermatology, Carrara Hospital, Carrara, Italy
| | - Luca Brandini
- Unit of Dermatology, San Giuseppe Hospital, Empoli, Italy
| | - Marzia Caproni
- Unit of Dermatologic Rare Disease and Skin Immunopathology, Department of Dermatology, University of Florence, Florence, Italy
| | | | - Roberto Cecchi
- Unit of Dermatology, San Jacopo Hospital, Pistoia, Italy
| | - Aldo Cuccia
- Unit of Dermatology, San Donato Hospital, Arezzo, Italy
| | - Michele Fimiani
- Section of Dermatology, Department of Clinical Medicine and Immunological Science, University of Siena, Siena, Italy
| | - Marta Grazzini
- Unit of Dermatology, Campo di Marte Hospital, Lucca, Italy
| | - Franco Marsili
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | | | | | | | - Camilla Peccianti
- Section of Dermatology, Department of Dermatology, Misericordia Hospital, Grosseto, Italy
| | | | - Nicola Pimpinelli
- Department of Surgery and Translational Medicine, Dermatology Clinic, University of Florence, Florence, Italy
| | - Francesca Prignano
- Department of Surgery and Translational Medicine, Dermatology Clinic, University of Florence, Florence, Italy
| | - Federica Ricceri
- Department of Surgery and Translational Medicine, Dermatology Clinic, University of Florence, Florence, Italy
| | | | - Susanna Rossari
- Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
| | | | - Walter Volpi
- Unit of Dermatologic Rare Disease and Skin Immunopathology, Department of Dermatology, University of Florence, Florence, Italy
| | - Michele Pellegrino
- Section of Dermatology, Department of Clinical Medicine and Immunological Science, University of Siena, Siena, Italy
| |
Collapse
|
20
|
Gualtieri B, Panduri S, Chiricozzi A, Romanelli M. Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy. GIORN ITAL DERMAT V 2018; 155:685-686. [PMID: 30249087 DOI: 10.23736/s0392-0488.18.06029-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Bruno Gualtieri
- Department of Dermatology, "Santi Giovanni e Paolo" Hospital, Venice, Italy -
| | | | | | | |
Collapse
|
21
|
Affiliation(s)
- Bruno Gualtieri
- Department of Dermatology, "Santi Giovanni e Paolo" Hospital, Venice, Italy -
| | | | | | | |
Collapse
|
22
|
Abstract
Acne fulminans (AF) is a rare acne variant characterized by sudden onset of painful nodules on the face, chest, and back in the presence of systemic symptoms. Pharmacologic agents such as steroid hormones and isotretinoin are well-known triggers, and several cases have been described. We report a case of AF occurring a few days after lymecycline therapy initiation.
Collapse
|
23
|
Gualtieri B, Maglie R, Tonini A, Panduri S, Chiricozzi A, Romanelli M. A giant annular rash in a woodman: the many faces of erythema chronicum migrans. GIORN ITAL DERMAT V 2018; 154:730-732. [PMID: 29600691 DOI: 10.23736/s0392-0488.18.05966-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Bruno Gualtieri
- Department of Dermatology, University of Pisa, Pisa, Italy -
| | - Roberto Maglie
- Section of Dermatology, Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
| | | | | | | | | |
Collapse
|
24
|
Tonini A, Gualtieri B, Panduri S, Romanelli M, Chiricozzi A. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. Expert Opin Biol Ther 2017; 18:135-148. [DOI: 10.1080/14712598.2018.1398729] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Chiricozzi A, Pimpinelli N, Ricceri F, Bagnoni G, Bartoli L, Bellini M, Brandini L, Caproni M, Castelli A, Fimiani M, Marsili F, Mazzatenta C, Niccoli MC, Panduri S, Pellegrino M, Sirna R, Volpi W, Romanelli M, Prignano F. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatol Ther 2017; 30. [PMID: 28940579 DOI: 10.1111/dth.12549] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 07/06/2017] [Accepted: 07/28/2017] [Indexed: 11/30/2022]
Abstract
Psoriasis is a chronic and relapsing inflammatory skin disease, clinically characterized by erythematous and scaly plaques. Treatment approach is mainly driven by disease severity, though several factors should be considered in order to identify the optimal therapeutic choice. Mild psoriasis may be treated with a wide array of topical agents including corticosteroids, vitamin D analogs, keratolytics, and calcipotriol/betamethasone propionate compound. Because guidelines may not provide practical indications regarding the therapeutic approach, the use of topical agents in psoriasis is more individually tailored. In order to homogenize the standard of care, at least in a local setting, we collected the real-life-based recommendations for the use of topical therapies from an expert panel, the Tuscany Consensus Group on Psoriasis, representing all leading centers for psoriasis established in Tuscany. With this document, this consensus group sought to define principles guiding the selection of therapeutic agents with straightforward recommendations derived from a real-life setting.
Collapse
Affiliation(s)
- Andrea Chiricozzi
- Dermatology Department, University of Pisa. Via Roma 67, 56126 Pisa, Italy
| | - Nicola Pimpinelli
- Department of Surgery and Translational Medicine, Section of Dermatology and Venereology, University of Florence School of Medicine, Florence, Italy
| | - Federica Ricceri
- Department of Surgery and Translational Medicine, Section of Dermatology and Venereology, University of Florence School of Medicine, Florence, Italy
| | | | - Laura Bartoli
- Dermatology Unit, San Jacopo Hospital, ASL 3, Pistoia, Italy
| | - Mauro Bellini
- Dermatology Unit, Carrara Hospital, USL nordovest, Carrara, Italy
| | - Luca Brandini
- Dermatology Unit, San Giuseppe Hospital, ASL 11, Empoli, Italy
| | - Marzia Caproni
- Dermatologic Rare Diseases and Skin Immunopathology Unit, University of Florence, Florence, Italy.,U.O. Dermatology I, University of Florence, Florence, Italy
| | | | - Michele Fimiani
- Departmernt of Dermatology, Division of Medical, Surgical and Neurosciences, University of Siena, Siena Italy
| | - Franco Marsili
- Dermatology Unit, Versilia Hospital, ASL 12, Lido di Camaiore, Lucca, Italy
| | | | | | - Salvatore Panduri
- Dermatology Department, University of Pisa. Via Roma 67, 56126 Pisa, Italy
| | - Michele Pellegrino
- Departmernt of Dermatology, Division of Medical, Surgical and Neurosciences, University of Siena, Siena Italy
| | - Riccardo Sirna
- Dermatology Unit, Misericordia Hospital, ASL 9, Grosseto, Italy
| | - Walter Volpi
- U.O. Dermatology I, University of Florence, Florence, Italy
| | - Marco Romanelli
- Dermatology Department, University of Pisa. Via Roma 67, 56126 Pisa, Italy
| | - Francesca Prignano
- Department of Surgery and Translational Medicine, Section of Dermatology and Venereology, University of Florence School of Medicine, Florence, Italy
| |
Collapse
|
26
|
Tonini A, Panduri S, D''''' Erme AM, Papadia F, Romanelli M, Krueger JG, Chiricozzi A. The management of moderate-to-severe chronic plaque psoriasis. Ital J Dermatol Venerol 2017; 152:447-457. [DOI: 10.23736/s0392-0488.17.05681-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
27
|
Panduri S, Mazzi A, Ghiara F, Janowska A, D' Erme AM, Oranges T, Romanelli M. Retroauricular angiolymphoid hyperplasia with eosinophilia: sustained long-term remission following treatment with corticosteroids. Ital J Dermatol Venerol 2017; 152:185-186. [PMID: 28166617 DOI: 10.23736/s0392-0488.16.05180-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Salvatore Panduri
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Amanda Mazzi
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Fabrizio Ghiara
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Agata Janowska
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Angelo M D' Erme
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy -
| | - Teresa Oranges
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marco Romanelli
- Division of Dermatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| |
Collapse
|
28
|
Chiricozzi A, Romanelli M, Panduri S, Donetti E, Prignano F. Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis. Histol Histopathol 2017; 32:893-898. [PMID: 28124315 DOI: 10.14670/hh-11-877] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Psoriasis is a chronic skin disease characterized by the activation of various T cell subsets secreting IFNγ, IL-17, and IL-22, dendritic cells producing TNFα and IFNα, and other immune cells including neutrophils and mast cells. Keratinocytes respond to different cytokine signals orchestrating innate and adaptive immune responses. In vitro studies sought to clarify the cytokine effects on keratinocytes in order to evaluate the centrality of these mediators in psoriasis pathogenesis. The aim of this review is to highlight the relevance of this peculiar in vitro approach in investigating cytokine effects on skin or multilayered epidermis. Particularly, we reported keynfindings supporting the cytokine role in psoriasis pathogenesis.
Collapse
Affiliation(s)
- A Chiricozzi
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
| | - M Romanelli
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - S Panduri
- Dermatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - E Donetti
- Department of Biomedical Sciences for Health, Laboratory of Structural and Ultrastructural Morphology, Università degli Studi di Milano, Milan, Italy
| | - F Prignano
- Department of Surgery and Translational Medicine, Section of Clinical Preventive and Oncology Dermatology, Università di Firenze, Florence, Italy
| |
Collapse
|
29
|
Chiricozzi A, Panduri S, Dini V, Tonini A, Gualtieri B, Romanelli M. Optimizing acitretin use in patients with plaque psoriasis. Dermatol Ther 2016; 30. [PMID: 27998019 DOI: 10.1111/dth.12453] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 10/23/2016] [Accepted: 10/31/2016] [Indexed: 11/27/2022]
Abstract
Acitretin is one of the systemic agents used for the treatment of psoriasis. Because different acitretin dosages resulted therapeutically successful, there is no general agreement on the optimal dose regimen. To report acitretin efficacy and safety in a real-life setting, wherein patient-tailored dose regimen is usually prescribed, a retrospective analysis evaluating charts of all plaque-type psoriasis patients treated with acitretin from the clinic database was performed. PASI score improvement, as well as PASI 50, 75, 90, and 100 responses were assessed throughout the observational period. Overall, 52% PASI score reduction and a satisfactory safety profile were detected. PASI 50, 75, 90, and 100 response was achieved by 53%, 48%, 28%, and 14%, respectively. Treatment consisted on a mean daily acitretin dose of 25.01 mg. The initial dose was increased (51.2% of cases) or decreased (48.8%) prescribing a mean daily dose of 29.8 mg and 20.02 mg, respectively. This study proposed a dose regimen customized on clinical response and patient's needs, to optimized acitretin benefit.
Collapse
Affiliation(s)
- Andrea Chiricozzi
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| | - Salvatore Panduri
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| | - Valentina Dini
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| | - Annalisa Tonini
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| | - Bruno Gualtieri
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| | - Marco Romanelli
- Dermatology Department, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| |
Collapse
|
30
|
Janowska A, Dini V, Panduri S, Macchia M, Oranges T, Romanelli M. Epidermal skin grafting in vitiligo: a pilot study. Int Wound J 2016; 13 Suppl 3:47-51. [PMID: 27547963 DOI: 10.1111/iwj.12632] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 06/10/2016] [Indexed: 11/30/2022] Open
Abstract
Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules and by the absence of functioning melanocytes. Treatment depends on the extent of the affected areas and on disease activity. Surgical techniques have proven to be effective in stable cases but can be time-consuming and, in some cases, aesthetically unsatisfying or painful for the patients. The aim of the study was to assess the clinical safety and effectiveness of a new automatic epidermal skin harvesting device in patients with stable localised vitiligo over a minimum 12-month period. This new system (CELLUTOME™ Epidermal Harvesting System, KCI, an ACELITY Company, San Antonio, TX) is a commercially available epidermal skin harvesting system that can be used without local anaesthesia or other pre-treatments and has been shown to have low rates of donor site morbidity. Epidermal skin grafts can used in patients with acute and hard to heal chronic wounds, burns and stable vitiligo. The use of advanced therapies may improve the quality of life, have cost benefits and accelerate re-pigmentation of patients with vitiligo. In our preliminary study, this system was seen to be a safe and efficacious means of harvesting epidermal micrografts containing melanocytes for use in patients with stable vitiligo unresponsive to standard therapies.
Collapse
Affiliation(s)
- Agata Janowska
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| | - Valentina Dini
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| | - Salvatore Panduri
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| | - Michela Macchia
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| | - Teresa Oranges
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| | - Marco Romanelli
- Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy
| |
Collapse
|
31
|
Affiliation(s)
- M. Romanelli
- Wound Healing research Unit, Department of Dermatology, University of Pisa, Italy
| | - G. Mulder
- University of California San Diego, California, US
| | - B. Paggi
- Wound Healing research Unit, Department of Dermatology, University of Pisa, Italy
| | - M. Macchia
- Wound Healing research Unit, Department of Dermatology, University of Pisa, Italy
| | - S. Panduri
- Wound Healing research Unit, Department of Dermatology, University of Pisa, Italy
| | - V. Dini
- Wound Healing research Unit, Department of Dermatology, University of Pisa, Italy
| |
Collapse
|
32
|
Romanelli M, Macchia M, Panduri S, Paggi B, Saponati G, Dini V. Clinical evaluation of the efficacy and safety of a medical device in various forms containing Triticum vulgare for the treatment of venous leg ulcers - a randomized pilot study. Drug Des Devel Ther 2015; 9:2787-92. [PMID: 26060395 PMCID: PMC4454208 DOI: 10.2147/dddt.s82712] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
This study was carried out to assess the efficacy and tolerability of the topical application of an aqueous extract of Triticum vulgare (TV) in different vehicles (cream, impregnated gauzes, foam, hydrogel, and dressing gel) for the treatment of venous lower leg ulcers. Fifty patients were randomized to receive one of the five investigational vehicles. Treatment was performed up to complete healing or to a maximum of 29 days. The wound size reduction from baseline was the primary efficacy variable, which was measured by means of a noninvasive laser scanner instrument for wound assessment. In all groups, apart from the foam group, a similar trend toward the reduction of the surface area was observed. The cream showed the greatest effect on the mean reduction of the lesion size. At last visit, six ulcers were healed: two in the cream group, three in the gauze group, and one in the dressing gel group. In the patients treated with the cream, the gauzes, the hydrogel, and the dressing gel, the reduction of lesion size was 40%–50%; the reduction was smaller in the foam group. No impact in terms of age on the healing process was found. The Total Symptoms Score decreased in all groups during the study; a greater efficacy in terms of signs/symptoms was observed in the patients treated with the gauzes. In the dressing gel group, one patient had an infection of the wound after 3 weeks of treatment and 2 of colonization, leading to a systemic antibiotic treatment. The events were judged as nonrelated to the device used. On the basis of the results, it could be argued that the medical device may be useful in the treatment of chronic venous ulcers.
Collapse
Affiliation(s)
- Marco Romanelli
- Wound Healing Research Unit, Dermatology Division, Department of Clinical and Experimental Medicine, University of Pisa, Lucca, Italy
| | - Michela Macchia
- Wound Healing Research Unit, Dermatology Division, Department of Clinical and Experimental Medicine, University of Pisa, Lucca, Italy
| | - Salvatore Panduri
- Wound Healing Research Unit, Dermatology Division, Department of Clinical and Experimental Medicine, University of Pisa, Lucca, Italy
| | - Battistino Paggi
- Wound Healing Research Unit, Dermatology Division, Department of Clinical and Experimental Medicine, University of Pisa, Lucca, Italy
| | | | - Valentina Dini
- Wound Healing Research Unit, Dermatology Division, Department of Clinical and Experimental Medicine, University of Pisa, Lucca, Italy
| |
Collapse
|